- Open Access
Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy
© Gunjal et al.; licensee BioMed Central. 2015
- Received: 23 January 2015
- Accepted: 10 March 2015
- Published: 28 March 2015
One of side effects of chemotherapy and radiotherapy is the induction of several factors in various tissues and organs that create a pro-metastatic microenvironment for cancer cells that survive initial treatment.
In the present study, we employed human ovarian cancer cell line A2780 and immunodeficient mice xenogrfat model to test effect of both ibuprofen and dexamethasone to ameliorate the therapy-induced pro-metastatic microenvironment in bone marrow, liver, and lung.
In our studies, we found that total body irradiation or administration of cisplatin increases the metastatic spread of human ovarian cancer cells transplanted into immunodeficient mice compared with animals unexposed to irradiation or cisplatin. Moreover, conditioned media harvested from irradiated murine bone marrow, lung, and liver chemoattracted human ovarian cancer cells, and this chemotactic activity was inactivated by heat, suggesting a major involvement of peptide or peptide-bound chemoattractants. We also observed that human ovarian cancer cells proliferate better if exposed to cell debris harvested from irradiated murine bone marrow. Finally, the pro-metastatic microenvironment in mice induced by radio- or chemotherapy was significantly ameliorated if animals were treated at the time of radiotherapy administration with non-steroid (ibuprofen) or steroid (prednisone) anti-inflammatory drugs.
In summary, we propose that a radiochemotherapy-induced, pro-metastatic microenvironment plays an important role in the metastasis of cancer cells that are resistant to treatment. Such cells have characteristics of cancer stem cells and are highly migratory, and simple, intensive, anti-inflammatory treatment by non-steroid agents to suppress induction of pro-metastatic factors after radiochemotherapy would be an interesting anti-metastatic treatment alternative.
- Prometastatic microenvironment
- Side effects of radiochemotherapy
- Ovarian cancer
After surgical removal of tumor tissue, chemotherapy and radiotherapy are the most efficient treatment modalities employed in clinical oncology. Unfortunately, anti-cancer treatment is usually associated with toxicity to non-tumor cells, resulting in different degrees of damage to tissues and organs [1,2]. There are well-known side effects of chemotherapy and radiotherapy that are mainly related to the toxicity to, and impaired function of, vital organs; however, the induction by these therapies of the expression of several factors in various organs that create a pro-metastatic microenvironment, is, surprisingly, not widely acknowledged.
In support of the reality of this effect, it is very well known that normal hematopoietic stem cells, after infusion into a host following myeloablative radiochemotherapy, home efficiently to bone marrow (BM) in response to several chemotactic factors upregulated in the BM microenvironment [3-5]. To explain this phenomenon, we hypothesized that toxic damage to BM and other organs as a result of radio and/or chemotherapy treatment of malignancies leads to upregulation of factors that attract normal circulating stem cells for regeneration but, unfortunately, also provide chemotactic signals to cancer cells that survive the initial treatment [1,6,7]. These cells may then establish tumor metastases.
In support of toxic damage as a driver of metastasis, we as well as others have demonstrated that exposure of mice to irradiation [8,4], cyclophosphamide [8,9], or vincristine [6,7] upregulates the levels of several chemokines and growth factors, such as stromal-derived factor 1 (SDF-1), hepatocyte growth factor/scatter factor (HGF/SF), vascular endothelial growth factor (VEGF), and monocyte chemotactic protein 1 (MCP-1), in the BM microenvironment [8-11]. We predicted that a similar response would accompany the toxic effects of chemotherapy or radiotherapy in other sensitive organs, including liver and lung [1,6,7].
In the present study, we report that conditioned medium (CM) from irradiated BM, lung, and liver chemoattracts human ovarian cancer cells in vitro. Next, by employing a short in vivo tumor cell tissue-seeding assay, we observed that increased numbers of human cancer cells seed (metastasize) to the BM and other organs in SCID-Beige immunodeficient mice after irradiation or exposure to chemotherapy. In addition, we observed that human cancer cells expanded more strongly in culture in the presence of a feeder layer of cell debris from damaged or dying human BM cells. Finally, we were able to (1) ameliorate the in vitro migration of cancer cells to CM harvested from irradiated tissues and (2) decrease seeding of in vivo-injected human cells into various organs in irradiated or chemotherapy-exposed mice by reducing the pro-inflammatory response induced by radiochemotherapy, due to administering either of the non-steroid anti-inflammatory drugs ibuprofen or dexamethasone.
We propose that a radiochemotherapy-induced pro-metastatic microenvironment, which plays an important but underappreciated role in the metastasis of cancer cells to bone and other organs (lungs or liver), can be ameliorated by a simple, intensive treatment by non-steroid and steroid anti-inflammatory agents to suppress induction of pro-metastatic factors by radiochemotherapy.
The A2780 ovarian epithelial cancer cell line was maintained in Roswell Park Memorial Institute (RPMI) medium 1640, containing 10% FBS, 100 U/ml penicillin, and 10 μg/ml streptomycin. Cells were cultured in a humidified atmosphere of 5% CO2 at 37°C, and the medium was changed every 48 hours.
Peritoneal tumor formation in mice
All procedures involving animals and their care were approved by the Institutional Animal Care and Use Committee, according to the guidelines of the association for Assessment and Accreditation of Laboratory Animal Care of the University of Louisville (Louisville, KY, USA).
Injection of A2780 cells into immunodeficient mice
To evaluate the in vivo metastatic behavior of A2780 cells, cells were injected intravenously (i.v.; 2 × 106 per mouse) into severe combined immunodeficient (SCID)-Beige inbred mice and divided into four groups (five mice per group). Group i) control (non-irradiated mice), ii) irradiated with 1000 cGy 24 hours prior to injection of A2780 cells, iii) control (untreated and non-irradiated), and iv) injected with cisplatin (5 mg/kg of body weight of mice) anticancer drug.
In a second experiment, mice were injected with an anti-inflammatory drug prior to irradiation (five mice per group). Mice were grouped as i) control (untreated and non-irradiated), ii) irradiated with 1000 cGy 24 h prior to injection of A2780 cells, iii) injected with ibuprofen (40 mg/kg of body weight of mice) only, iv) injected with ibuprofen (40 mg/kg of body weight of mice) and irradiated with 1000 cGy, v) injected with dexamethasone (2.5 mg/kg body weight of mice) only, and vi) injected with dexamethasone (2.5 mg/kg body weight of mice) and irradiated with 1000 cGy. In both experiments, all control animals were injected with A2780 cells only. Experimental strategies are shown in (Figure 1).
Bone marrows, spleens, livers, and lungs were removed 48 hours after injection of these cells, and the presence of ovarian cells (i.e., murine–human chimeras) was evaluated by the level of human α-satellite DNA expression. DNA was amplified in the extracts isolated from BM-, spleen-, liver-, and lung-derived cells using real-time PCR. Briefly, DNA was isolated using the QIAamp DNA Mini kit (Qiagen), and human satellite and murine β-actin DNA levels was detected by means of real-time PCR using an ABI Prism 7500 Sequence Detection System. A 25-μl reaction mixture containing 12.5 μl SYBR Green PCR Master Mix, 300 ng DNA template, forward (5′-ACC ACT CTG TGT CCT TCG TTC G-3′) and reverse (5′-ACT GCG CTC TCA AAA GGA GTG T-3′) primers for the α-satellite, and forward (5′-TTC AAT TCC AAC ACT GTC CTG TCT -3′) and reverse (5′- CTG TGG AGT GAC TAA ATG GAA ACC -3′) primers for the β-actin were used. The Ct value was determined as described previously , and the number of human cells present in the murine organs (the degree of chimerism) was calculated from the standard curve obtained by mixing different numbers of human cells with a constant number of murine cells. In long-term experiments, cells (2.5 × 106 per mouse) were inoculated intraperitoneally into SCID-Beige inbred mice (seven mice per group). Four weeks later, the mice were sacrificed for evaluation of the A2780 cells present in BM, spleen, liver, and lung. Detection of human cells was performed as described below (Additional file 1: Figure S1, panel A).
Flow cytometric analysis of HLA expression
BM cells were harvested from mice at day 30 following transplantation of A2780 cells. Mice were grouped (four mice per group) according to treatment: i) no irradiation or ii) irradiation with 1000 cGy 24 hours prior to A2780 cell transplantation. BM cells were then washed twice with sterile PBS and incubated with 1X RBC lysis solution, and the intact cells were stained for human leukocyte antigen (HLA) Additional file 1: Figure S1, panel B. Staining was performed in PBS with 2% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), at 4°C for 30 min. Cells were subsequently washed, resuspended, and analyzed using an LSR II flow cytometer (BD Biosciences). At least 1.5 × 106 events were acquired from each sample, and FlowJo software was used for analysis (Tree Star, Ashland, OR).
Preparation of conditioned media
Pathogen-free C57BL/6 mice (7–8 weeks old) were used for these experiments. Mice (four per group) were irradiated with 1000 cGy, and 24 hours later, bone marrow, liver, and lung were isolated. Conditioned medium (CM) was obtained after 3 hours of incubation of BM, liver, or lung cells (mechanically homogenized 30x using a syringe) in RPMI at 37°C. After centrifugation, the supernatant was used for further experiments. In studies with anti-inflammatory drugs, mice were injected intraperitoneally with ibuprofen (40 mg/kg) or dexamethasone (2.5 mg/kg) prior to irradiation with 1000 cGy. Twenty-four hours later, organs were isolated, and CM from various organs was prepared as described above.
Chemotaxis assays were performed in a modified Boyden’s chamber with 8-μm pore polycarbonate membrane inserts (Costar Transwell; Corning Costar, Lowell, MA, USA) as described previously . In brief, cells were detached with 0.05% trypsin and seeded into the upper chamber of an insert at a density of 5 × 104 in 110 μl. The lower chamber was filled with pre-warmed CM harvested from the different organs from irradiated SCID-Beige mice at 1000 cGy. Medium supplemented with 0.5% BSA was used as a negative control, and medium supplemented with 10% FBS was used as a positive control. After 48 hours, the inserts were removed from the Transwell supports. The cells that had not migrated were scraped from the upper membrane with a cotton swab, and the cells that had transmigrated to the lower side of the membrane were fixed and stained with HEMA 3 (Protocol, Fisher Scientific, Pittsburgh, PA) and counted on the lower side of the membrane using an inverted microscope.
Temperature effect on BM CM
CM samples from irradiated mouse BM were subjected to a range of temperatures. In particular, they were: i) incubated for 30 min at 37°C, 42°C, 56°C, or 90°C and ii) subjected to three frost–defrost cycles, which were carried out by incubating these CM samples at −80°C and subsequently in a water bath at 37°C. The samples were then directly used for chemotaxis experiments, and any residual samples were stored at −80°C for further use.
Molecular centrifugation of BM CM
CM samples from irradiated mouse BM were centrifuged at 3000 × g for 30 min in Centricon centrifugal filter devices (Millipore) until the entire sample had passed through the column. These devices were used for the separation of proteins and peptides, covering a range of molecular-weight cutoffs (10, 30, 50, and 100 kDa). CM samples filtered and concentrated using different molecular-weight cutoffs were then used for chemotaxis assays with A2780 cells.
Invasive potential of ovarian cancer cells grown on dying or damaged bone marrow cells
C57BL/6 GFP mice were grouped (three per group) as non-irradiated or irradiated (with 1000 cGy). Twenty-four hours later, bone marrow, liver, and lung were isolated, and CM samples were obtained from these organs, as described above. After 3 hours, cells flushed from bone marrow were then co-cultured with A2780 cells (1000 cells/well in 24-well plates). Both BM cells and CM samples from other organs were analyzed as a growth-supporting medium for A2780 cells. Forty eight hours later, A2780 cell clusters were counted and photographed under a fluorescence microscope, and GFP-expressing BM cells were also counted by FACS.
All results were presented as mean ± SD. Statistical analysis of the data was performed using the nonparametric Mann–Whitney test (animal studies) and Student’s t test for unpaired samples by using Graph Pad Prism software. P < 0.05, P < 0.005 and P < 0.0005 were considered significant.
Increased seeding efficiency of human ovarian cancer cells in a mouse xenograft model after chemotherapy and irradiation
Anti-inflammatory treatment at the time of irradiation reduces the metastatic spread of human ovarian cancer cells in immunodeficient mice
Human ovarian cancer cells respond to a chemotactic gradient of factors released from irradiated organs
Based on these results, we became interested in pinpointing the molecular characteristics of the chemotactic factors present in CM harvested from BM. Figure 4B shows an initial analysis of these CM sample by employing heat inactivation (left panel) and molecular centrifugation (right panel). The results indicate that chemotactic factors are heat sensitive, which suggests a peptide- or protein-associated structure, and are in the range of 30–50 kDa in size. We are currently trying to identify these factors by employing mass spectrophotometry analysis.
Lethally irradiated BM tissue supports growth of human cancer cells
The coincidence between inflammation and tumorogenesis is well established as well as the fact that cancer frequently develops in tissues exposed to chronic inflammation [12,13], which orchestrates the microenvironment around growing tumors, contributing to proliferation, survival, and migration of malignant cells [12-14]. Therefore, it is not surprising that both non-steroid and steroid anti-inflammatory drugs are employed in cancer patients in some protocols [15,16].
Specifically, non-steroid, anti-inflammatory drugs such as the cyclooxygenase-1 and −2 inhibitor ibuprofen or the more potent and selective COX-2 inhibitor celecoxib appear to reduce the risk of developing cancer and may inhibit prostaglandin- and thromboxane-dependent cell division, metastasis, and angiogenesis and promote the apoptosis of malignant cells [17,18]. On the other hand, synthetic corticosteroids, such as dexamethasone, are also used in oncology in patients undergoing chemotherapy to counteract certain side effects, such as emesis, or to counteract edema in brain tumors [19,20]. Dexamethasone is also used as a direct chemotherapeutic agent in certain hematological malignancies [21,22].
In the present study, we employed both ibuprofen and dexamethasone to ameliorate the therapy-induced pro-metastatic microenvironment in bone marrow, liver, and lung. Based on our experimental models and results, we propose a potential application of anti-inflammatory treatment for cancer patients by administration of a COX-2 inhibitor or dexamethasone at the time of radiochemotherapy to reduce the metastatic spread of cancer cells to different organs. This strategy is based on the finding that exposure of mice to γ-irradiation or systemic administration of cisplatin induces a pro-metastatic microenvironment in BM, liver, spleen and lung (Figures 2 and 3). The salient observation of our work is that administration of ibuprofen or dexamethasone at the time of radiochemotherapy inhibits the spread of human ovarian cancer cells to several organs of immunodeficient mice. This is relatively a simple approach that is effective at significantly decreasing the seeding efficiency of human malignant cells to several organs after they are injected intravenously. This essay has been developed by our group to study early metastatic spread of tumor cells [6,7]. However, we are aware that more experiments are needed to evaluate metastatic potential of cancer cells over time. We also show that ovarian cancer cells grow and expand much better when exposed to debris from BM-irradiated cells. Again, these studies performed on established tumor cell line need further clarification in real clinical settings employing patient cancer cells that survived radio-chemotherapy treatment.
It is well known that metastasis is responsible for more than 90% of cancer-associated mortality [23,24] and is a multistep process in which induction of a pro-metastatic microenvironment within tumors and at distant locations plays a crucial role. Chemotactic factors emerging in damaged tissues may induce an undirected motility of cancer cells, described as chemokinesis , or a directed migration, known as chemotaxis . In response to chemokinesis and/or chemotaxis, cancer cells leave a primary tumor, infiltrate surrounding tissues, and may enter the lymphatics or peripheral blood to metastasize to remote organs [1,6-8]. Several peptide-based and non-peptide-based factors, such as bioactive lipids or extracellular nucleotides, have been described as inducing the motility of cancer cells [4,6,7,27]. On the other hand, enhanced migratory properties are one of the key features of stem cells . The comparatively strong resistance of cancer therapy supports the concept of presence of cancer stem cells [29-32]. These cells would survive treatment and are most likely responsible for malignant spread after the initial reduction of the primary tumor. Since metastasis and tumor spread is a major factor limiting survival of cancer patients, the clinical need to prevent or target metastasis is a therapeutic priority in clinical oncology.
It is well known that tumors respond to several pro-metastatic chemotactic factors, and therefore it would be difficult to inhibit their metastatic potential by inhibiting just one or even a few receptor axes [4,6,7,33]. For example, in a model of metastatic rhabdomyosarcoma, we previously demonstrated that exposure to irradiation [4,6,7] or chemotherapy [6-8] of several organs upregulates the levels of chemokines and growth factors, such as SDF-1, HGF/SF, VEGF, and MCP-1, in addition to bioactive lipids such as S1P, C1P, LPA, and LPC, which are endowed with strong chemotactic activities with respect to normal as well as malignant cells [3,6,7]. As in chemotherapeutics, exposure to irradiation leads also to the release of several alarmines (e.g., ATP and UTP) from the damaged cells (manuscript in preparation). Moreover, in several well-controlled animal experimental models, it has been demonstrated that blockade of CXCR4 [4,33,34], CXCR7 , or c-Met [4,36] receptors by employing small-molecule inhibitors; downregulation of these receptors by shRNA strategies [27,37]; in vivo administration of blocking antibodies against SDF-1  or MCP-1 [39,40]; or application of S1P-binding aptamers  significantly diminishes chemotherapy- or radiotherapy-related dissemination of tumor cells to various organs. Since it is impossible to target all these pro-metastatic factors at the same time, it is obvious that future anti-metastatic drugs must depend on potent molecules that interfere with migration and adhesion processes of cancer cells downstream of the surface receptors for these pro-metastatic factors.
However, the aim of our current work was not to identify particular factors involved in radiochemotherapy-induced metastatic spread of cancer cells. but rather to broadly characterize their molecular properties. Our preliminary experiments, performed in a model of human ovarian cancer, indicate the involvement of temperature-sensitive factors that are present in the 30–50-kDa fraction of normal serum. While this fraction is most likely to contain a peptide-based chemoattractant (s), we cannot exclude the possibility that it may contain certain bioactive lipids that are associated with proteins. Further studies will address this issue. We are also aware that the metastatic spread of cancer cells after radiochemotherapy could also be promoted by other mechanisms. One of these mechanisms could be direct toxicity to the endothelial wall, which affects the integrity of the endothelial barrier, and may facilitate seeding of cancer cells into damaged organs through the disrupted endothelium . Another possibility is that membrane fragments (e.g., exosomes or microvesicles) have been shown in several animal models to be endowed with chemotactic properties [41,42]. Furthermore, we must remember that our results were obtained with a human ovarian cancer cell line, and cells from other tumors may respond differently to a panel of chamoattractants.
In conclusion, we propose that a radiochemotherapy-induced pro-metastatic microenvironment plays an important role in the metastasis of cancer cells that are resistant to treatment. Such cells possess characteristics of cancer stem cells and are highly migratory, and a simple, intensive treatment with anti-inflammatory agents to suppress induction of pro-metastatic factors after radiochemotherapy is an interesting treatment alternative. However, this hypothesis requires further dose-optimization studies and validation in appropriate clinical trials. Finally, as we have also demonstrated in a model of irradiated BM, cell debris from organs damaged by radiochemotherapy may support expansion of cancer cells and could provide an underappreciated “fertile soil” for metastasizing cancer cells, as suggested in the well-known seed and soil hypothesis of cancer metastasis .
This work was supported by NIH grants 2R01 DK074720, R01HL112788, the Stella and Henry Endowment, and Maestro grant 2011/02/A/NZ4/00035 to MZR.
- Ratajczak MZ, Jadczyk T, Schneider G, Kakar SS, Kucia M. Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res. 2013;6:95.View ArticlePubMed CentralPubMedGoogle Scholar
- Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467–88.View ArticlePubMed CentralPubMedGoogle Scholar
- Kim CH, Wu W, Wysoczynski M, Abdel-Latif A, Sunkara M, Morris A, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia. 2012;26:106–16.View ArticlePubMed CentralPubMedGoogle Scholar
- Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003;63:7926–35.PubMedGoogle Scholar
- Ratajczak MZ, Kim CH, Abdel-Latif A, Schneider G, Kucia M, Morris AJ, et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia. 2012;26:63–72.View ArticlePubMedGoogle Scholar
- Schneider G, Bryndza E, Abdel-Latif A, Ratajczak J, Maj M, Tarnowski M, et al. Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy. Mol Cancer Res. 2013;11:793–807.View ArticlePubMed CentralPubMedGoogle Scholar
- Schneider G, Sellers ZP, Abdel-Latif A, Morris AJ, Ratajczak MZ. Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy. Mol Cancer Res. 2014;12:1560–73.View ArticlePubMedGoogle Scholar
- Ratajczak M, Tarnowski M, Staniszewska M, Sroczynski T, Banach B. Mechanisms of cancer metastasis: involvement of cancer stem cells? Minerva Med. 2010;101:179–91.PubMedGoogle Scholar
- Park SI, Liao J, Berry JE, Li X, Koh AJ, Michalski ME, et al. Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res. 2012;72:2522–32.View ArticlePubMed CentralPubMedGoogle Scholar
- Cachaco AS, Carvalho T, Santos AC, Igreja C, Fragoso R, Osorio C, et al. TNF-alpha regulates the effects of irradiation in the mouse bone marrow microenvironment. PLoS One. 2010;5:e8980.View ArticlePubMed CentralPubMedGoogle Scholar
- Suzuki M, Tsujikawa M, Itabe H, Du ZJ, Xie P, Matsumura N, et al. Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. J Cell Sci. 2012;125:2407–15.View ArticlePubMed CentralPubMedGoogle Scholar
- Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.View ArticlePubMedGoogle Scholar
- de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118–37.View ArticlePubMedGoogle Scholar
- Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.View ArticlePubMedGoogle Scholar
- Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 2007;30:947–53.PubMedGoogle Scholar
- Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol. 2009;1:29–43.View ArticlePubMed CentralPubMedGoogle Scholar
- Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev. 2003;12:1486–91.PubMedGoogle Scholar
- Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and Non-steroidal Anti-inflammatory Drugs Can Prevent Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2015;135:975–83.View ArticlePubMedGoogle Scholar
- Galicich JH, French LA, Melby JC. Use of dexamethasone in treatment of cerebral edema associated with brain tumors. J Lancet. 1961;81:46–53.PubMedGoogle Scholar
- Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2012;4:233–42.View ArticleGoogle Scholar
- Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27:5008–14.View ArticlePubMedGoogle Scholar
- Kadia TM, Kantarjian HM, Thomas DA, O’Brien S, Estrov Z, Ravandi F, et al. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014;90:120–4.View ArticlePubMedGoogle Scholar
- Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58.View ArticlePubMedGoogle Scholar
- Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8:341–52.View ArticlePubMedGoogle Scholar
- Liu Z, Klominek J. Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors. Anticancer Res. 2004;24:1625–30.PubMedGoogle Scholar
- Wiggins H, Rappoport J. An agarose spot assay for chemotactic invasion. Biotechniques. 2010;48:121–4.View ArticlePubMedGoogle Scholar
- Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J, et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer. 2010;127:2554–68.View ArticlePubMed CentralPubMedGoogle Scholar
- Mukherjee S, Mazumdar M, Chakraborty S, Manna A, Saha S, Khan P, et al. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/beta-catenin negative feedback loop. Stem Cell Res Ther. 2014;5:116.View ArticlePubMedGoogle Scholar
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.View ArticlePubMedGoogle Scholar
- Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.View ArticlePubMed CentralPubMedGoogle Scholar
- Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106:13820–5.View ArticlePubMed CentralPubMedGoogle Scholar
- Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65:9328–37.View ArticlePubMedGoogle Scholar
- Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 2002;100:2597–606.View ArticlePubMedGoogle Scholar
- Brennecke P, Arlt MJ, Campanile C, Husmann K, Gvozdenovic A, Apuzzo T, et al. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin Exp Metastasis. 2014;31:339–49.View ArticlePubMed CentralPubMedGoogle Scholar
- Luker KE, Lewin SA, Mihalko LA, Schmidt BT, Winkler JS, Coggins NL, et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 2012;31:4750–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010;12:1–10.View ArticlePubMed CentralPubMedGoogle Scholar
- Sekula M, Miekus K, Majka M. Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo. Int J Oncol. 2014;44:1853–60.PubMed CentralPubMedGoogle Scholar
- Belperio JA, Phillips RJ, Burdick MD, Lutz M, Keane M, Strieter R. The SDF-1/CXCL 12/CXCR4 biological axis in non-small cell lung cancer metastases. Chest. 2004;125:156S.View ArticlePubMedGoogle Scholar
- Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417–24.View ArticlePubMedGoogle Scholar
- Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009;11:1235–42.View ArticlePubMed CentralPubMedGoogle Scholar
- Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–60.View ArticlePubMedGoogle Scholar
- Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006;46:1199–209.View ArticlePubMedGoogle Scholar
- Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.